Investigation of product quality between extemporaneously compounded progesterone vaginal suppositories and an approved progesterone vaginal gel

Drug Development and Industrial Pharmacy

Volumn 30, Issue 10, 2004, Pages 1069-1078

  Mahaguna, Vorapann ^a   McDermott, J Mario ^a   Zhang, Feng ^a   Ochoa, Felipe ^a  

^a LLC   (United States)

Author keywords

Compounding; Gel; Progesterone; Suppository; Vagina

Indexed keywords

PROGESTERONE;

ARTICLE; DELFTIA ACIDOVORANS; DRUG FORMULATION; DRUG STERILITY; FOOD AND DRUG ADMINISTRATION; GEL; GOOD MANUFACTURING PRACTICE; PHARMACY; SUPPOSITORY;

CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; DRUG PACKAGING; DRUG STABILITY; HUMANS; HYDROGEN-ION CONCENTRATION; INDUSTRIAL MICROBIOLOGY; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; PHARMACEUTICAL SERVICES; PHARMACOPOEIAS; PRESERVATIVES, PHARMACEUTICAL; PROGESTERONE; QUALITY CONTROL; SUPPOSITORIES; TEMPERATURE; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 9644257166     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.1081/DDC-200040251     Document Type: Article

References (16)

1. American Medical Association. Family Medical Guide, 3rd Ed.; Clayman, C.B., Ed.; Random House, Inc.: New York, 1994; 25.
2. Pesko, L.J. Progesterone suppositories. Am. Drug. (USA) 1990, 201 (1), 52-53.
3. Price, J.H.; Ismail, H.; Gorwill, R.H.; Sarda, I.R. Effect of the suppository base on progesterone delivery from the vagina. Fertil. Steril. 1983, 39 (4), 490-493.
4. The United States Pharmacopoeia Convention. The United States Pharmacopoeia XXVII-National Formulary XXII; The United States Pharmacopoeia Convention, Inc.: Rockville, MD, 2004.
5. Report: Limited FDA Survey of Compounded Drug Products; http://www.fda.gov/cder/pharmcomp/survey.htm (accessed Sep 2004).
6. Azechi, Y.; Ishikawa, K.; Mizuno, N.; Takahashi, K. Sustained release of diclofenac from polymer-containing suppository and the mechanism involved. Drug Dev. Ind. Pharm. 2000, 26 (11), 1177-2283.
7. The Council of Europe. The European Pharmacopoeia 4.0; The Council of Europe: Strasbourg, France, 2004.
8. Allen, L.V. The basics of compounding: compounding suppositories, part two- extemporaneous preparation. Int. J. Pharm. Compd. 2000, 4 (5), 371-373.
9. Duncan-Hewitt, W.; Rains, J. Compounded suppositories and pharmaceutical care. Int. J. Pharm. Compd. 1997, 1 (2), 93-99.
10. Allen, L.V. The basics of compounding: compounding suppositories, part one- theoretical considerations. Int. J. Pharm. Compd. 2000, 4 (4), 289-293.
11. Al-Achi, A.; Webster, K.; Greenwood, R.; Nicol, S. Assaying progesterone in extemporaneously prepared suppositories. Int. J. Pharm. Compd. 1997, 1 (5), 339.
12. Fulper, L.D.; Cleary, R.W.; Harland, B.C.; Hikal, A.H.; Jones, A.B. Liquefaction times of fatty-type suppositories with and without progesterone. Am. J. Hosp. Pharm. (USA) 1990, 47 (3), 602-603.
13. Caillouette, J.C.; Sharp, C.F.; Zimmerman, G.J.; Roy, S. Vaginal pH as a marker for bacterial pathogens and menopause status. Am. J. Obstet. Gynecol. 1997, 176 (6), 1270-1275.
14. Russell, A.D. Challenge testing: principles and practice. Int. J. Cosmet. Sci. 2003, 25, 147-153.
15. Iwata, M.; Takahashi, Y.; Shirotake, S.; Takayama, K.; Nagai, T. Effect of sodium caprate on the absorption of progesterone from mixed suppositories administered to the vagina of rabbits. Drug Dev. Ind. Pharm. 1997, 23, 167-172.
16. Cicinelli, E.; Cignarelli, M.; Sabatelli, S.; Romano, F.; Einer-Jensen, N. Plasma concentrations of progesterone are higher in the uterine artery than in the radial artery after vaginal administration of micronized progesterone in an oil based solution to postmenopausal women. Fertil. Steril. 1998, 69, 471-473.